









市场行情
/
股票
/
nasdaq-celu
/

Celularity Inc

CELU

1.450USD

+0.200+16.00%

收盘 12/19, 16:00（美东）报价延迟15分钟

40.91M总市值

亏损市盈率 TTM



Celularity Inc

1.450

+0.200+16.00%

概览公司财务分析

概览

公司

财务

分析

关于 Celularity Inc 公司

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Celularity Inc简介



公司代码CELU

公司名称Celularity Inc

上市日期May 23, 2019

CEOHariri (Robert J)

员工数量123

证券类型Ordinary Share

年结日May 23

公司地址170 Park Ave

城市FLORHAM PARK

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编07932

电话19087682170

网址https://celularity.com/

公司代码CELU

上市日期May 23, 2019

CEOHariri (Robert J)

Celularity Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+0.11%

Mr. Vincent Levien

Independent Director

3.70K

Mr. Stephen A. Brigido

President - Degenerative Disease

Ms. Diane L. Parks

Independent Director

Dr. Peter H. Diamandis, M.D.

Independent Director

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

Mr. Joseph Dossantos

Interim Chief Financial Officer

Mr. Carlos Ramirez

Senior Vice President - Investor Relations

名称

名称/职务

职务

持股

持股变动

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+0.11%

Mr. Vincent Levien

Independent Director

3.70K

Mr. Stephen A. Brigido

President - Degenerative Disease

Ms. Diane L. Parks

Independent Director

Dr. Peter H. Diamandis, M.D.

Independent Director

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月20日周四

持股股东

股东类型

持股股东

占比

Genting Bhd

22.36%

Hariri (Robert J)

10.09%

Starr International Company, Inc.

5.39%

Lincoln Alternative Strategies LLC

4.34%

C.V. Starr & Co., Inc.

2.70%

其他

55.11%

持股股东

占比

Genting Bhd

22.36%

Hariri (Robert J)

10.09%

Starr International Company, Inc.

5.39%

Lincoln Alternative Strategies LLC

4.34%

C.V. Starr & Co., Inc.

2.70%

其他

55.11%

股东类型

持股股东

占比

Corporation

26.71%

Individual Investor

12.96%

Investment Advisor

8.87%

Insurance Company

2.70%

Investment Advisor/Hedge Fund

1.32%

Hedge Fund

0.39%

Research Firm

0.19%

Family Office

0.04%

其他

46.82%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

3.82M

13.73%

2025Q3

3.82M

16.36%

+119.97K

2025Q2

3.70M

17.46%

+189.07K

2025Q1

120

3.51M

18.18%

-579.52K

2024Q4

135

3.39M

17.70%

+120.20K

2024Q3

149

3.27M

18.60%

+20.75K

2024Q2

160

3.32M

18.56%

+109.90K

2024Q1

166

3.20M

18.29%

-780.71K

2023Q4

164

3.20M

20.76%

-511.70K

2023Q3

164

3.71M

20.21%

+96.25K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Genting Bhd

6.34M

23.74%

Jul 24, 2025

Hariri (Robert J)

2.85M

10.7%

+3.28K

+0.12%

May 15, 2025

Starr International Company, Inc.

1.53M

5.73%

May 15, 2025

Lincoln Alternative Strategies LLC

1.23M

4.61%

+1.23M

Jul 14, 2025

C.V. Starr & Co., Inc.

764.07K

2.86%

Jun 30, 2025

The Vanguard Group, Inc.

500.13K

1.87%

Jun 30, 2025

Diamandis (Peter)

134.31K

0.5%

-63.82K

-32.21%

May 15, 2025

Parks (Diane L.)

23.61K

0.09%

-67.42K

-74.06%

May 15, 2025

Geode Capital Management, L.L.C.

134.82K

0.51%

-1.22K

-0.89%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

DFA Dimensional US Sustainability Core 1 ETF

iShares Micro-Cap ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

公告日期

类型

比率

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

常见问题

Celularity Inc的前五大股东是谁？



Celularity Inc 的前五大股东如下：
Genting Bhd持有股份：6.34M，占总股份比例：23.74%。
Hariri (Robert J)持有股份：2.85M，占总股份比例：10.70%。
Starr International Company, Inc.持有股份：1.53M，占总股份比例：5.73%。
Lincoln Alternative Strategies LLC持有股份：1.23M，占总股份比例：4.61%。
C.V. Starr & Co., Inc.持有股份：764.07K，占总股份比例：2.86%。